TREATMENT OF CNS DISEASES WITH sGC STIMULATORS
개요
발명자
Joon Jung; Thomas Wai-Ho Lee; Rajesh R. Iyengar; Nicholas Robert Perl; Peter Germano; Maria D. Ribadeneira; Kim Tang
IPC 분류
CPC 분류
The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3′5′-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable.
원문 (중국어)
The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3′5′-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable.